Cost analysis comprises one component within comprehensive evaluations and asks, in comparison to other alternatives, Is the program worth what it costs? Is it cost-effective? Do the benefits justify ...

Jeremy Smith discusses the cost:benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them while still promoting R&D.

The proportion of rules reviewed by OMB that sport cost and benefit documentation is rather insignificant compared to the broader body of rules. Moreover entire categories of intervention—such ...